Truist analyst Danielle Brill initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $56 price target Palvella is in a sweet spot for biotech investment with QTORIN, a de-risked potential pipeline in a product with clean proof-of-concept data in microcystic lymphatic malformations, a rare genetic skin disease, a registrational trial that has been optimized to replicate Phase 2 findings, and a potential blockbuster opportunity with no marketed competition, the analyst tells investors in a research note. The firm sees a value inflection approaching in the next 5-9 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes
- Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential
- Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
- Palvella Therapeutics granted sixth U.S. patent covering rapamycin
- Palvella Therapeutics Holds Annual Stockholders Meeting